At AACR 2024, we explored the poster hall to pick out the posters that would interest the BioTechniques reader and those we found delivered the most interesting or surprising findings. Get our ...
IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a commercial-stage company focused on improving outcomes for breast cancer patients worldwide by providing physicians and patients with next ...
WALTHAM, Mass. and BOULDER, Colo., April 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences (COGT), Inc. , a biotechnology company focused on developing precision therapies for genetically defined ...
CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (QLGN) today announces that a poster featuring its early clinical experience with a novel first-in-class G-Quadruplex ...
‒ Poster for GP2 Phase IIb clinical trial final efficacy analysis was presented during the 2020 San Antonio Breast Cancer Symposium (SABCS) today ‒ Phase IIb clinical trial was a prospective, ...
Aggressive-variant prostate cancer features and therapeutic outcomes in patients with de-novo metastatic hormone-sensitive prostate cancer. This is an ASCO Meeting Abstract from the 2026 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results